Volume 16, Issue 4 (Volume 16, No 4 2026)
Dermatol Cosmet. 2026, 16(4): 268-276 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Barkhordarioon A. A comprehensive review of the epidemiological, pathophysiological, and therapeutic aspects of androgenetic alopecia based on the latest evidence. Dermatol Cosmet. 2026; 16 (4) :268-276
URL: http://jdc.tums.ac.ir/article-1-5828-en.html
URL: http://jdc.tums.ac.ir/article-1-5828-en.html
Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran , aa.barkhordari78@gmail.com
Abstract: (15 Views)
Androgenetic alopecia (AGA) is the most common form of non-scarring hair loss in both men and women, characterized by progressive miniaturization of hair follicles in androgen-sensitive areas. This condition is usually genetically determined and influenced by androgenic hormones, particularly dihydrotestosterone (DHT). The present review aims to summarize the epidemiological, pathophysiological, clinical, and therapeutic aspects of AGA based on the most recent scientific evidence up to 2025. Current evidence indicates that AGA is not merely a cosmetic issue but also a significant factor affecting patients’ psychological and social well-being. Available treatments include FDA-approved medications such as finasteride and minoxidil, as well as emerging modalities such as platelet-rich plasma (PRP) injection, microneedling, and low-level laser therapy. However, limited efficacy, the need for long-term treatment, and the occurrence of adverse effects have prompted ongoing research into novel and combination therapeutic approaches.
Keywords: androgenetic alopecia, hair loss, minoxidil, finasteride, platelet-rich plasma, dihydrotestosterone
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
